A connection between inflammation and cancer has been long suspected. New insights into the molecular link between inflammation and tumorigenesis would be beneficial for the development of novel strategies that target inflammation for use in both cancer prevention and therapy. New molecules that control inflammatory responses would provide a novel therapeutic possibility to prevent and reduce the incidence of cancer. Triggering receptor expressed on myeloid cells 1 (TREM-1) is one of these potential candidates. TREM-1 plays a crucial role in enhancing inflammatory responses through amplifying the expression of proinflammatory cytokines and chemokines. TREM-1 has limited expression;it is expressed on neutrophils and can be induced on monocytes and macrophages. We have determined that inhibition of TREM-1 affects liver tumorigenesis. Our preliminary data suggest that deletion of the Trem1 gene provides resistance to development of chemical-induced hepatocellular carcinoma in a murine model. We have identified a previously unknown TREM-1 ligand, HMGB1 (High Mobility Group Box1) that is released by necrotic hepatocytes and is involved in activation of Kupffer cells, which creates an inflammatory environment that, in turn, causes hepatocyte compensatory proliferation, leading to carcinogenesis. Our data reveal an essential contribution of TREM-1 on Kupffer cells in regulating or co-regulating the inflammatory response to inducers of chronic inflammation in damaged tissues. Thus, we have identified novel induction mechanisms of chronic inflammation leading to carcinogenesis. This application addresses the analysis of a new function of TREM-1 in tumorigenesis. The goal of this research is to determine the impact and mechanisms of TREM-1 regulation of liver tumorigenesis and to design better strategies for potent anti-cancer prevention and development of new therapeutic approaches that target immune and non-immune components in liver tumors. The central hypothesis of this application, based on our strong preliminary data involving TREM-1-deficient mice, is that inhibition of TREM-1 modulates inflammatory responses, which results in diminished development of hepatocellular carcinoma. This knowledge will be crucial in designing the most potent treatment of inflammation- associated cancer. Our hypothesis is reflected in our study of the impact and mechanisms of TREM-1 regulation in tumorigenesis, the potential of inhibitors of TREM-1 to suppress the development of chemical- or oncogene-induced liver tumorigenesis (Specific Aim 1), and the function of TREM-1 in liver cancer cells (Specific Aim 2). Data obtained from these studies will reveal the role of TREM-1 in modulation of tumorigenesis and will aid in development of novel strategies that can be translated into the clinic for prevention and therapy of liver cancer. Additionally, this research may benefit patients with a variety of inflammatory diseases, including allergy and autoimmune diseases.

Public Health Relevance

The goal of this research is to study the role of TREM-1 in controlling initiation and progression of liver tumorigenesis. The knowledge gained from the proposed research should help develop strategies for potent anti-cancer prevention and novel clinical and preclinical therapeutic approaches that target the immune and non-immune components of liver tumors. Additionally, this research may benefit patients with a variety of inflammatory diseases, including allergy and autoimmune diseases.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
1R01CA172230-01A1
Application #
8632080
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Jhappan, Chamelli
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Georgia Regents University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Augusta
State
GA
Country
United States
Zip Code
30912